6UQR
Complex of IgE and Ligelizumab
Summary for 6UQR
Entry DOI | 10.2210/pdb6uqr/pdb |
Descriptor | Ligelizumab, IgE, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total) |
Functional Keywords | anti-ige antibody, complex, monoclonal, immune system |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 4 |
Total formula weight | 114692.55 |
Authors | Tarchevskaya, S.S.,Kleinboelting, S.,Jardetzky, T.S. (deposition date: 2019-10-21, release date: 2019-12-04, Last modification date: 2023-10-11) |
Primary citation | Gasser, P.,Tarchevskaya, S.S.,Guntern, P.,Brigger, D.,Ruppli, R.,Zbaren, N.,Kleinboelting, S.,Heusser, C.,Jardetzky, T.S.,Eggel, A. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun, 11:165-165, 2020 Cited by PubMed: 31913280DOI: 10.1038/s41467-019-13815-w PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.65029109708 Å) |
Structure validation
Download full validation report